Evidence map›Paper›PMID 26636483›Full record

ArticleCell cycle (Georgetown, Tex.)2016

Lactate promotes glutamine uptake and metabolism in oxidative cancer cells.

Jhudit Pérez-Escuredo, Rajesh K Dadhich, Suveera Dhup, Andrea Cacace, Vincent F Van Hée, Christophe J De Saedeleer, Martina Sboarina, Fabien Rodriguez, Marie-Joséphine Fontenille, Lucie Brisson and 2 more

Abstract read
In one paragraph

Article in Cell cycle (Georgetown, Tex.), 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 138 papers.

0numbers the graph read from it
0cells of the map it votes in
138citing papers in PubMed
4.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

138 citing papers in PubMed, 215 citations in OpenAlex.

  1. Review
  2. Review
  3. Article
  4. Article
  5. Review
  6. Review
  7. Review
  8. Review
  9. Article
  10. Review
  11. mFrontiers in cell and developmental biology · 2026
    Review
  12. Glucose and Lactate, Starters or Intermediates of Cancer Metabolic Rewiring.Advances in experimental medicine and biology · 2026
    Review
  13. Article
  14. Review
  15. Review
  16. Article
  17. Long noncoding RNAs regulating enzymatic reactions in cancer.Experimental & molecular medicine · 2025
    Review
  18. Review
  19. Article
  20. Review

78 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors at 1 institution in 1 country.

Jhudit Pérez-Escuredoa From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Rajesh K Dadhicha From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Suveera Dhupa From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Andrea Cacacea From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Vincent F Van Héea From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Christophe J De Saedeleera From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Martina Sboarinaa From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Fabien Rodrigueza From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Marie-Joséphine Fontenillea From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Lucie Brissona From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Paolo E Porporatoa From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
Pierre Sonveauxa From the Pole of Pharmacology, Institute of Experimental and Clinical Research (IREC), Université catholique de Louvain (UCL) Medical School , Brussels , Belgium.
UCLouvain · BE

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Oxygenated cancer cells have a high metabolic plasticity as they can use glucose, glutamine and lactate as main substrates to support their bioenergetic and biosynthetic activities. Metabolic optimization requires integration. While glycolysis and glutaminolysis can cooperate to support cellular proliferation, oxidative lactate metabolism opposes glycolysis in oxidative cancer cells engaged in a symbiotic relation with their hypoxic/glycolytic neighbors. However, little is known concerning the relationship between oxidative lactate metabolism and glutamine metabolism. Using SiHa and HeLa human cancer cells, this study reports that intracellular lactate signaling promotes glutamine uptake and metabolism in oxidative cancer cells. It depends on the uptake of extracellular lactate by monocarboxylate transporter 1 (MCT1). Lactate first stabilizes hypoxia-inducible factor-2α (HIF-2α), and HIF-2α then transactivates c-Myc in a pathway that mimics a response to hypoxia. Consequently, lactate-induced c-Myc activation triggers the expression of glutamine transporter ASCT2 and of glutaminase 1 (GLS1), resulting in improved glutamine uptake and catabolism. Elucidation of this metabolic dependence could be of therapeutic interest. First, inhibitors of lactate uptake targeting MCT1 are currently entering clinical trials. They have the potential to indirectly repress glutaminolysis. Second, in oxidative cancer cells, resistance to glutaminolysis inhibition could arise from compensation by oxidative lactate metabolism and increased lactate signaling.

Indexed as

AnimalsBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1GlutaminaseGlutamineHeLa CellsHumansLactic AcidMaleMiceMice, Inbred BALB CMice, NudeMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersNeoplasmsOxidation-ReductionBasic Helix-Loop-Helix ProteinsEndothelial PAS Domain-Containing Protein 1GLS protein, humanGlutaminaseGlutamineLactic AcidMonocarboxylate Transport Protein 1Monocarboxylic Acid TransportersSymportersCancerc-MycGlutamineglutaminolysishypoxia-inducible factor-2 (HIF-2)Hypoxia-inducible factor (HIF)lactate signalingmonocarboxylate transporter 1 (MCT1)Tumor metabolism

Identifiers

PMID26636483
PMCPMC4825768
OpenAlexW2184384535

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.